To study the severity of mutation G85E, located in the first membrane spanning domain of the CFTR gene, we studied the clinical features of 13 Spanish patients with cystic fibrosis (CF) carrying this mutation. G85E accounts for about 1% of Spanish CF alleles. One patient was homozygous G85E/G85E and the rest were compound heterozygotes for G85E and other mutations (AF508 nine patients, A1507 two patients, and 712-1G>T one patient). The characteristics of the pooled G85E/any mutation group were compared with those of 30 AF508 homozygotes. Mean age at diagnosis and percentage of ideal height for age were higher in the G85E/any mutation group (4.2 (SD 4.7) v 2.4 (SD 2.3), p<0.05, and 102.8 (SD 4.7) v 97.8 (SD 4.1), p<0.01)), both probably related to the greater prevalence of pancreatic sufficiency (70% v 0%, p<0O01). The G85E homozygote was pancreatic sufficient. Sweat sodium levels were slighdy higher, and salt loss related problems more frequent, in the G85E/any group. Two of the G85E patients died of respiratory failure aged 6 and 14 years. Striking discordance in the phenotype was observed in two pairs of sibs, one of them dizygotic twins, suggesting that factors, genetic and environmental, other than CFTR genotype are important in determining CF phenotype.
Abstract
To study the severity of mutation G85E, located in the first membrane spanning domain of the CFTR gene, we studied the clinical features of 13 Spanish patients with cystic fibrosis (CF) carrying this mutation. G85E accounts for about 1% of Spanish CF alleles. One patient was homozygous G85E/G85E and the rest were compound heterozygotes for G85E and other mutations (AF508 nine patients, A1507 two patients, and 712-1G>T one patient). The characteristics of the pooled G85E/any mutation group were compared with those of 30 AF508 homozygotes. Mean age at diagnosis and percentage of ideal height for age were higher in the G85E/any mutation group (4.2 (SD 4.7) v 2.4 (SD 2.3), p<0.05, and 102.8 (SD 4.7) v 97.8 (SD 4.1), p<0.01)), both probably related to the greater prevalence of pancreatic sufficiency (70% v 0%, p<0O01). The G85E homozygote was pancreatic sufficient. Sweat sodium levels were slighdy higher, and salt loss related problems more frequent, in the G85E/any group. Two of the G85E patients died of respiratory failure aged 6 Some of the features of classical CF may sometimes be lacking leading to "mild" or "atypical" forms.-'7 Many mutations associated with such phenotypes are missense substitutions in the membrane spanning domains (MSD) of the CFTR.7 9-15 Some of these mutant proteins are normally processed and located in the apical membrane, and lead to cAMP regulated Clcurrents,'5 although smaller than normal (class IV mutations6). Conversely missense mutations located in the nucleotide binding folds are usually severe.'8 Other mutations associated with mild CF are some splicing mutations in which low levels of normal transcripts are produced. 6 17 We present here the clinical findings in 13 Spanish CF patients carrying the missense mutation G85E, a G to A change at nucleotide position 386 in exon 3, which results in a glutamic acid for glycine substitution at codon 85 in the first MSD of the CFTR. '9 Clinical data of the patients were obtained from several centres. Patients [7] [8] [9] [10] [11] [12] 3 . Direct sequencing allowed us to identify the G85E mutation. The microsatellite haplotype 16-24-13 (IVS8CA-IVS 17bTA-IVS 17bCA)23 was used to study CF samples with uncharacterised mutations from 160 CF patients. G85E was found in 13 samples.
All chromosomes with mutation G85E were associated with the same microsatellite haplotype 16-24-13. Nine patients were compound heterozygotes for AF508/G85E, one pair of sibs were G85E/AI507, one was G85E/712-1 G>T, and one was a G85E homozygote. Data from G85E/AF508 and G85E/non-AF508 patients were pooled for comparison with those from AF508 homozygotes. The G85E/any mutation patients were older at diagnosis, had a higher percentage of ideal height, and a lower prevalence of PI (30% v 100%, p<0.01) compared with the AF508 homozygotes ( and Spain (1 %) (T Casals, personal communication). This mutation causes the substitution of a negatively charged amino acid for an uncharged one within the first MSD. The molecular mechanism of the CFTR dysfunction associated with G85E has recently been found to consist of a trafficking defect (class II mutation)6 with rapid degradation of the mutant protein before transit through the Golgi complex.26 There have been only three reports on the clinical characteristics associated with this mutation. Chalkley and Harris27
described an 11 year old boy, homozygous for G85E, with PS. Kerem et af8 reported five G85E homozygotes and eight compound 
